

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Inventor: José A. Soto

**A SOLUTION COMPRISING SEA WATER AS EXPECTORANT AND
VIRUCIDAL FOR THE TREATMENT OF RESPIRATORY DISEASES AND
METHOD TO USE AND DEVELOP**

SANCHELIMA & ASSOCIATES, P.A.

Jesus Sanchelima, Esq.,

Reg. No. 28,755

Attorneys for Applicant

235 S.W. Le Jeune Road

Miami, Florida 33134

Tel: (305) 447-1617

Fax: (305) 445-8484

1 **I. TITLE: " A SOLUTION COMPRISING SEA WATER AS**
2 **EXPECTORANT AND VIRUCIDAL FOR THE TREATMENT OF**
3 **RESPIRATORY DISEASES AND METHOD TO USE AND DEVELOP "**
4

5 **II. BACKGROUND OF THE INVENTION**
6

7 **1. Field of the Invention.**
8

9 The present invention relates to the use of a solution as expectorant
10 and decongestant, and more particularly, to the use of the solution made of
11 filtered natural sea water comprising pharmaceutically active salts and
12 trace elements having a direct effect in the respiratory tissues and
13 secretions as expectorant, mucolytic, decongestant and virucidal.
14

15 **2. Other Related Applications.**
16

17 The present application is a continuation-in-part of pending of U.S.
18 Patent Application Serial No. 10/431,721, filed on 5/9/2003, which is hereby
19 incorporated by reference.
20

21 **3. Description of the Related Art.**
22

23 Research on the above referenced have been published in the
24 following:
25

26 Betakova, T. and Moss, B.; *Disulfide Bond and Membrane Topology of the*
27 *Vaccinia Virus A17L Envelope Protein*, March 2000. Journal of Virology.
28 Vol. 74, No.5, p. 2438-2442.

1 St J Jones, P; Korte, T and Blumenthal, R; *Conformational Changes in*
2 *Cell Surface HIV -1 Envelope Glycoproteins are Triggered by Cooperation*
3 *between Cell Surface CD4 and Co-receptors*. 1998; J. Bio I. C. 273: 404-409.

4
5 Tuma R, Bamford JH, Bamford DR, et al; *Structure, Interactions and*
6 *Dynamics of PDR1 virus II. Organization of the Viral Membrane and*
7 *DNA*. 1996; Journal of Molecular Biology. March 22; 257 (1): 102-15

8
9 Applicant believes that the closest reference corresponds to
10 applicant's own patent application. The present application, however,
11 includes subject matter not disclosed in the parent application, particularly,
12 since the use of a solution made of filtered natural sea water comprising
13 pharmaceutically active salts and trace elements is claimed, wherein the
14 solution has a direct effect in respiratory tissues and secretions as
15 expectorant, mucolytic, decongestant, and virucidal.

16
17 Applicant believes that a close reference corresponds to US Patent
18 No. 4,822,512 issued to Auchincloss for Biocidal, particularly virucidal,
19 compositions. However, it differs from the present invention because
20 Auchincloss teaches a dry, water-soluble biocidal composition comprising
21 (a) 0.01 to 5 parts by weight of water-soluble inorganic halide, (b) 25 to 60
22 parts by weight of an oxidizing agent which, in aqueous solution, reacts
23 with the halide to generate hypohalite ions, (c) 3 to 8 parts by weight of
24 sulfamic acid, (d) 0 to 20 parts by weight of a non-reducing organic acid, (e)
25 10 to 30 parts by weight of an anhydrous alkali metal phosphate, the parts
26 by weight of the composition totaling 100, the pH of a 1% by weight
27 aqueous solution of the composition being between 1.2 and 5.5, and the
28 composition being characterized by lack of evolution of halogen at a pH

1 less than 3.0 and a biocidal activity substantially greater than that
2 produced by like compositions having inorganic halide concentrations
3 greater than about 20%.

4
5 Furthermore, Auchincloss teaches the use of biocidal and virucidal
6 compositions that could be used safely on farm animals. The composition
7 benefits include that it is non-corrosive, non-irritant to the skin or eyes in
8 its aqueous form, and it can be sprayed in rooms without discomfort. The
9 composition solvent includes sea water. In addition, the composition
10 comprises sodium chloride, potassium persulfate and sulfonate, which
11 produce virucidal activity. However, the composition's pH is extremely
12 acidic and it is used to spray livestock buildings, calves, piglets and horses.

13
14 Clinical examination of the skin and mucous membranes of the
15 livestock established no inflammatory or any other adverse response on the
16 part of the animals.

17
18 Animal viruses can be divided into two major categories, naked
19 viruses and enveloped viruses.

20
21 Naked viruses contain only ribonucleic acids "RNA" or
22 deoxyribonucleic acids "DNA" and a protein coat. Enveloped viruses also
23 contain RNA or DNA plus a protein coat, and a lipid containing
24 membrane, also called envelope. The naked and enveloped viruses are
25 intracellular obligated parasites. However, to cause infection of other cells,
26 they may be exposed to the environment or surrounding tissues. This
27 phase is called the infectious phase.

1 Known prior art shows that proteins and lipids, which are stabilized
2 by disulfide chemical bonds, form viral membrane. Membrane
3 components such as hemagglutinins are anchored to the viral membrane
4 by hydrophobic bonds. The membrane structure is held together by both
5 types of chemical links, covalent and non covalent bonds. During viral
6 infections, the viruses penetrate the cells through a mechanism defined as
7 fusion. This is a form of viral penetration through the cellular walls, into
8 the cytoplasm of the cell, and it requires a low acid pH.

9
10 Applicant believes that another close reference corresponds to US
11 Patent No. 6,534,075 issued to Hei, et al. for Antimicrobial and antiviral
12 compositions and treatments for food surfaces. However, it differs from
13 the present invention because Hei, et al. teaches an antimicrobial and
14 antiviral composition in powder form or in the form of a two part liquid
15 concentrate for washing and sanitizing foods, food surfaces, food ware,
16 process waters, animal quarters, and animal carcasses. The composition
17 may also be used to reduce the microbial and viral population on animals;
18 reducing human pathogenic microbes, reducing opportunistic pathogenic
19 microbes on eggs, and treating skin diseases. The composition includes
20 three reactive species, which in solution form an oxidizing species, and
21 optionally a food grade acid source. The reactive species include a natural
22 source of a quaternary or protonizable nitrogen compound, which is
23 acceptable on foods, an oxidant and a halide source.

24
25 Other patents describing the closest subject matter provide for a
26 number of more or less complicated features that fail to solve the problem
27 in an efficient and economical way. None of these patents suggest the
28 novel features of the present invention.

III. SUMMARY OF THE INVENTION

A therapeutic solution comprised of filtered seawater and firstly administered in the form of an aerosolized solution in the respiratory tract of mammals. The therapeutic solution has a direct effect in respiratory tissues and secretions as expectorant, mucolytic, decongestant and virucidal.

The therapeutic solution is further characterized in that the filtered seawater comprises a mixture of cations selected from the group consisting of sodium, magnesium, calcium and potassium, and anions selected from the group consisting of chloride, and sulfate.

The therapeutic solution is further characterized in that the filtered seawater comprises approximately 277.00 - 555.00 millimoles per liter sodium, 417.00 - 894.00 millimoles per liter chloride, 9.80 - 11.70 millimoles per liter potassium, 20.90 - 26.13 millimoles per liter sulfate, 45.60 - 60.49 millimoles per liter magnesium, and 8.11 - 10.87 millimoles per liter calcium, wherein osmolality is 920 to 1,130 mOsm/Kg and pH is 5.7 - 6.8.

The therapeutic solution is further characterized in that the filtered seawater comprises trace elements and a therapeutic solvent. The therapeutic solvent is the seawater.

The therapeutic solution is further characterized in that the therapeutic solution is firstly administered by aerosol to the respiratory tract of the mammals such that the therapeutic solution contacts areas

1 where the mucosa secretions accumulate including nose, pharynx, larynx,
2 trachea, bronchi, bronchioles and alveoli.

3
4 The therapeutic solution is further characterized in that the
5 therapeutic solution is secondly administered by nebulization with a dose
6 of approximately between one to ten ml via nasal or oral cavity to reach
7 intratracheobronchial tissues and secretions, with a varying frequency of
8 administration according the mammals age group and clinical diagnosis.
9 The nebulization every two to twelve hours and extending three to fifteen
10 minutes. The therapeutic solution may be thirdly administered in a dry
11 form through inhalations of one to three per time.

12
13 The therapeutic solution is further characterized in that the
14 therapeutic solution is fourthly administered with tents and/or a
15 vaporization system in a continuous form for up to twenty-four hours or
16 more.

17
18 The instant invention is also a method of affecting respiratory tissues
19 and secretions as expectorant, mucolytic, decongestant and virucidal in a
20 mammal in need thereof, comprising administering to the mammal an
21 effective amount of a therapeutic solution. The therapeutic solution is
22 comprised of filtered seawater and firstly administered in the form of an
23 aerosolized solution.

24
25 The method also includes the therapeutic solution firstly
26 administered as an aerosolized solution via nasal or oral cavity to reach
27 intratracheobronchial tissues and the secretions.

1 The method also includes the therapeutic solution increases the
2 solubility and volume of the phlegm in a respiratory tract reducing the
3 adhesiveness and making them easier to expel by means of coughing or
4 suctioning, providing a symptomatic relief of cough and congestion
5 associated with the bronchial asthma, acute and chronic bronchitis, and
6 common colds.

7
8 The method also includes the therapeutic solution increases output of
9 the secretions from the respiratory tract by stimulating ciliary movement,
10 which facilitate the removal of mucus.

11
12 The method also includes the therapeutic solution stimulates water
13 transport into an airway lumen to decrease the inflammatory changes in a
14 respiratory tree associated with bronchial asthma, acute and chronic
15 bronchitis, and common colds.

16
17 The method also includes the therapeutic solution is secondly
18 administered by nebulization with a dose of approximately between one to
19 ten ml of via nasal or oral cavity to reach intratracheobronchial tissues and
20 the secretions with a varying frequency of administration according to the
21 mammals age group and clinical diagnosis. Nebulizations every two to
22 twelve hours and extending three to fifteen minutes.

23
24 The instant invention is also a method of preparing a therapeutic
25 solution, comprising:

26
27 A) extracting seawater from a depth beyond where microscopic
28 organism known as plankton lives, in an ocean;

- 1 B) filtering said seawater to obtain desired concentration of
2 elements, said elements primarily comprising sodium, magnesium,
3 calcium, potassium, chloride, and sulfate;
4 C) testing said seawater for microbiological and chemical analysis;
5 and
6 D) preparing a solution for packaging, having a predetermined
7 approximated seawater element content as expectorant, mucolytic,
8 decongestant, and virucidal.

9

10 It is therefore one of the main objects of the present invention to
11 provide a solution made of filtered natural sea water comprising
12 pharmaceutically active salts and trace elements that have a direct effect in
13 respiratory tissues and secretions when administered.

14

15 It is another object of this invention to provide a solution made of
16 filtered natural sea water comprising pharmaceutically active salts and
17 trace elements that are expectorant, mucolytic, decongestant and have a
18 virucidal effect when administered.

19

20 It is another object of the present invention to provide a solution
21 made of filtered natural sea water comprising pharmaceutically active salts
22 and trace elements, for solution aerosol administration in the form of vials.

23

24 It is yet another object of the present invention to provide a solution
25 having a low acid pH that allows viral penetration through cellular walls,
26 into the cytoplasm of a cell.

27

1 It is still another object of this invention to provide such a solution
2 that is inexpensive to manufacture and administer while retaining its
3 effectiveness.

4
5 Further objects of the invention will be brought out in the following
6 part of the specification, wherein detailed description is for the purpose of
7 fully disclosing the invention without placing limitations thereon.

8 9 **IV. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

10
11 Seawater is processed to obtain pharmacologically active solutions
12 for the treatment of respiratory diseases.

13
14 The solution of the instant invention is administered to mammals for
15 the intratracheobronchial treatment of respiratory illnesses in the form of
16 nebulizations. The solution is placed in a plastic receptacle or alike, to be
17 delivered into the respiratory system organs using a pressure gradient to
18 transport the solution and its active ingredients in a gaseous form.

19
20 The solution is administered into the tracheobronchial tract through
21 the nasal or oral cavity and the power source necessary to introduce the
22 preparation may be breathed air (inhalation) of a patient himself or a
23 power source other than the breathed air of the patient, such as, but not
24 limited to, a balloon method, air compressor, ultrasonic systems or alike.

25
26 The doses and frequency of the treatments may vary according with
27 the diagnosis and the patients' age. The usual dose of a nebulization may
28 be between 1 to10 ml of the solution via nasal or oral cavity to reach the

1 intratracheobronchial tissues and secretions. In a dry form, administration
2 may be through inhalations / puffs of one to three per time. The frequency
3 of administration may change as well according with the patient age group
4 and the clinical diagnosis. One nebulization every 2 to 8 hours is usual.
5 The typical time expended on each nebulization is between 3 to 15 minutes.

6
7 Aerosol treatments can be given also using tents and/or a
8 vaporization system to create the desired effect. In these cases, the time of
9 vaporization may be twenty-four hours or more.

10
11 The aerosols have an expectorant effect by humidification of
12 tenacious sputum accumulated in the respiratory organs. Small drops
13 delivered directly into the tissues where the respiratory secretions
14 accumulate, change their chemical constitution and physical shape to a
15 more liquid form easier to expel out of the respiratory tree.

16
17 Without being bound by any theory, the present inventor believes
18 that the solution has a direct effect in respiratory tissues and secretions as
19 expectorant, mucolytic, decongestant and virucidal.

20
21 The solution and/or its variants may be used as a vehicle for other
22 drugs to be delivered into the respiratory tract of a mammal. This adds a
23 synergistic effect to different medications used for the treatment of
24 respiratory problems such as bronchial asthma, acute and chronic
25 bronchitis and common colds. Properties of the solution include anti-
26 inflammatory, mucolytic, decongestant, expectorant and virucidal. These
27 properties add a therapeutic effect to the patient when combined with
28 other drugs and administered via aerosol. The use of this solution as a

1 vehicle in any form or concentration makes administered medication more
2 effective, since the key elements dissolved in their natural form, sea water,
3 remain in constant proportions.
4

5 Without being bound by any theory, the present inventor believes
6 that another condition that can be treated with the claimed invention is
7 chronic obstructive pulmonary disease, better known as "COPD". COPD
8 comprises a group of symptoms and clinical signs caused by several
9 diseases. The diseases include two major entities defined as: chronic
10 bronchitis and pulmonary emphysema. In addition, a third entity includes
11 bronchiectasis.
12

13 Although there is a common clinical and pathological ground for
14 these type of respiratory disorders, pulmonary emphysema is
15 characterized by alveolar septum destruction and periods of exacerbation.
16 Symptoms of pulmonary emphysema include cough, sputum production,
17 shortness of breath, and the presence of pulmonary sepsis.
18

19 Bronchiectasis is a terminology reserved for cases of extreme
20 bronchial dilatation and secondary infection characterized by thick sputum
21 production and cough. Brochiectasis can occur as a complication of
22 emphysema, bronchitis or other pulmonary problems. In addition,
23 genetical forms of brochiectasis have been analyzed.
24

25 All the above conditions have symptoms that improve with the use of
26 the solution. Additionally, outcomes of preliminary studies indicate that
27 the solution has a mucolytic effect on the sputum, changing its chemical

1 and physical composition, which allows the patient an easier way to expel
2 it from respiratory tissues.

3
4 Without being bound by any theory, the present inventor believes
5 that the solution has an antiviral effect causing the death of viruses in
6 respiratory infections, during the infectious phase of their cycle.

7
8 The present invention also includes a method of treatment using the
9 solution to inhibit and destroy enveloped respiratory viruses through an
10 effect of a direct action on the viral coating structures. This is the lipid
11 containing membrane called envelope and the protein coat. The slightly
12 acid pH of the solution made from sea water allows a chemical reaction of
13 the pharmacologically active salts with the disulfide bonds that normally
14 stabilize membrane structures. As a result, a cleavage occurs and the viral
15 permeability is altered. The virus becomes osmotically fragile. Additional
16 conformational changes occur and provoke a fusion like stage, as a result of
17 these reactions on the membrane and the protein coat, the nucleic acids are
18 exposed and subsequently destroyed.

19
20 The solution also has a virucidal effect over naked viruses, viruses
21 containing only ribonucleic acid or deoxyribonucleic acid and a protein
22 coat. Once the solution low pH and its pharmacologically active salts, in
23 reaction with the disulfide bonds, induce the conformational changes, the
24 nucleic acids are exposed. Hydrogen bonds between the bases that hold
25 together the two strands of nucleotide, react with the pharmacological salts
26 that conform the active ingredients of the solution. This allows the
27 separation of the strands, this is the thermodynamic reaction. The final
28 result is the direct elimination of the viruses by a detergent like effect. The

1 inhibition of the virus's pathogenicity causes a significant improvement
2 and symptoms relief of the mammals suffering from viral respiratory
3 infections.

4
5 Without being bound by any theory, the present inventor also
6 believes that the solution has a therapeutic effect against viruses affecting
7 the respiratory tract of mammals, particularly in those affected by
8 respiratory diseases where this viruses can cause severe damaged. This
9 includes, but is not limited to asthma, acute bronchitis, chronic obstructive
10 pulmonary disease and common colds. The solution also has a
11 prophylactic effect against viral infections in mammals receiving its
12 aerosolized form.

13
14 The solution may be administered for a virucidal effect in a dry form
15 as well as using an aerosol system to deliver the active salts into the
16 respiratory tract. The solution obtains a desired action over respiratory
17 viruses and is tolerable for mammals' respiratory tissues.

18
19 In the preferred embodiment, the instant invention is a solution
20 having pharmacological compositions containing the elements seen in
21 Chart 1 below or the pharmacologically acceptable salts thereof, for aerosol
22 administration in the form of vials.

23
24 Examples of the solution packaging according to the invention are:

25
26 i) vials containing 1 to 30 ml of the solution for aerosol
27 administration; and

1 ii) multi-dose containers carrying 50 to 1000 ml of the solution for
2 aerosol administration.

3
4 The present invention also includes a method of preparing a solution,
5 comprising:

6
7 A) extracting seawater from a depth beyond where microscopic
8 organism known as plankton lives, in an ocean;

9 B) filtering said seawater to obtain desired concentration of
10 elements, said elements primarily comprising sodium, magnesium,
11 calcium, potassium, chloride, and sulfate;

12 C) testing said seawater for microbiological and chemical analysis;
13 and

14 D) preparing a solution for packaging, having a predetermined
15 approximated seawater element content as expectorant, mucolytic,
16 decongestant, and virucidal.

17
18 Step A) of the method includes, extracting seawater from a depth
19 beyond where microscopic organism known as plankton lives, in an ocean.
20 Typically, the depth beyond where the plankton lives is seven meters. In
21 the preferred embodiment, the extraction is done in an area exposed to
22 open ocean.

23
24 Step B) of the method includes, filtering said seawater to obtain the
25 desired concentration of elements, said elements primarily comprising
26 sodium, magnesium, calcium, potassium, chloride, and sulfate. The
27 seawater is filtered using a density filter for a decantation process using a
28 multilayer cellulose filter to remove undesired particles and to obtain the

desired solution concentration. In the preferred embodiment, only two layers of cellulose filters are utilized for the decantation process to obtain a more natural concentration of salts.

Step C) of the method includes, testing said seawater for microbiological and chemical analysis. The seawater is radiated using ultraviolet light to preserve its sterility. Solution samples are collected and tested for microbiological and chemical analysis. Once this process is concluded, the solution is stored in a metallic receptacle at a steady temperature. The resulting solution comprises a formulation of six key elements, making approximately ninety-nine percent of the dissolved solids: sodium, magnesium, calcium, potassium, chloride, and sulfate.

Step D) of the method includes, preparing a solution for packaging, having a predetermined approximated seawater element content as expectorant, mucolytic, decongestant, and virucidal. The packaging may be in the form of vials containing 1 to 30 ml of the solution for aerosol administration, and / or multi-dose containers carrying 50 to 1000 ml of the solution for aerosol administration. However, other containers housing the solution may be utilized for effective administration.

The specification of an example solution prepared according to the described method is seen in chart 1 below. It is noted that mmol/l is millimoles per liter. The elements listed are an average, and may fluctuate, as it is noted that they are derived from the ocean. However, it is noted that the result is a solution comprising a formulation of six key elements making ninety-nine percent of the dissolved solids.

	FROM	TO
	mmol/L	mmol/L
SODIUM	277.00	555.00
CHLORIDE	417.00	894.00
POTASSIUM	9.80	11.70
SULFATE	20.90	26.13
MAGNESIUM	45.60	60.49
CALCIUM	8.11	10.87
Osmolality: 920 to 1130 mOsm /Kg		
pH 5.7 to 6.8.		

Chart 1

The solution of Chart 1 may additionally contain natural trace elements, as seen in Chart 2 below, of significant amounts approximating:

	mg/l
CARBON	28.0
BROMINE	67.0
STRONTIUM	8.0
FLUORIDE	1.3
IODINE	0.06
LITHIUM	0.18
RUBIDIUM	0.12
NITROGEN	11.5
PHOSPHORUS	0.06
SILICON	2.0
ARGON	0.43
BARIUM	(}.{)2
MOL YBDENUM	0.01
BORON	4.4

Chart 2

Furthermore, the solution of Chart 2 may additionally contain smaller amounts of natural trace elements, as seen in Chart 3 below, approximating:

	mg/l		mg/l
URANIUM	0.0032	NEON	0.00012
VANADIUM	0.0025	MANGANESE	0.0001
TITANIUM	0.001	CADMIUM	0.0001
ZINC	0.0005	COPPER	0.0001
NICKEL	0.00048	TUNGSTEN	0.0001
ALUMINUM	0.0004	IRON	0.000055
CESIUM	0.0004	XENON	0.00005
CHROMIUM	0.0003	ZIRCONIUM	0.00003
ANTIMONY	0.00024	BISMUTH	0.00002
KRYPTON	0.0002	NIOBIUM	0.00001
SELENIUM	0.0002	THALLIUM	0.00001

Chart 3

The presence of trace elements, seen in Charts 2 and 3, although not part of the key components, is considered essential for the solution because they are part of the compound as a whole in the form of pharmacologically stable salts or isolated elements. Thus having beneficial effects as part of the medical treatments.

The type of the trace elements will vary with the seawater origin, so may its concentration. The solvent for the solution is the seawater. The compounds of the invention, as well as the pharmaceutically acceptable salts thereof, due to the pharmacological properties and very low toxicity can be used as active ingredients for the preparation of medicaments for the respiratory diseases.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

After testing the solution in human volunteers, it showed not to be irritant to the mucosa of the respiratory tree, mouth or the eye tissues. The compound was well tolerated in its aerosol protocol.

The foregoing description conveys the best understanding of the objectives and advantages of the present invention. Different embodiments may be made of the inventive concept of this invention. It is to be understood that all matter disclosed herein is to be interpreted merely as illustrative, and not in a limiting sense.